Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Inclusion Criteria: * The decision to initiate treatment with commercially available Ozempic has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study. * The participant with T2DM is scheduled to start treatment with Ozempic based on the clinical judgment of their treating physician as specified in the approved label in Korea. * Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male/female age greater than or equal to (\>=) 19 years at the time of signing informed consent. Exclusion Criteria: * Participants who are or have previously been on Ozempic therapy. * Known or suspected hypersensitivity to Ozempic, the active substance or any of the excipients. * Previous participation in this study. Participation is defined as having given informed consent in this study. * Female patients who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice). * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.